QQQ   375.47 (+0.76%)
AAPL   148.76 (+1.51%)
MSFT   308.23 (+0.31%)
FB   339.99 (+1.39%)
GOOGL   2,864.74 (+0.32%)
TSLA   864.27 (-0.67%)
AMZN   3,444.15 (-0.08%)
NVDA   222.90 (+0.31%)
BABA   177.00 (+6.10%)
NIO   40.03 (+1.06%)
CGC   14.34 (+8.64%)
GE   104.73 (+0.59%)
AMD   116.33 (-0.09%)
MU   67.57 (+0.46%)
T   25.59 (+1.03%)
F   15.42 (-0.90%)
ACB   7.45 (+7.66%)
DIS   171.18 (+0.02%)
PFE   42.09 (+1.86%)
BA   215.97 (-0.47%)
AMC   40.80 (-5.18%)
QQQ   375.47 (+0.76%)
AAPL   148.76 (+1.51%)
MSFT   308.23 (+0.31%)
FB   339.99 (+1.39%)
GOOGL   2,864.74 (+0.32%)
TSLA   864.27 (-0.67%)
AMZN   3,444.15 (-0.08%)
NVDA   222.90 (+0.31%)
BABA   177.00 (+6.10%)
NIO   40.03 (+1.06%)
CGC   14.34 (+8.64%)
GE   104.73 (+0.59%)
AMD   116.33 (-0.09%)
MU   67.57 (+0.46%)
T   25.59 (+1.03%)
F   15.42 (-0.90%)
ACB   7.45 (+7.66%)
DIS   171.18 (+0.02%)
PFE   42.09 (+1.86%)
BA   215.97 (-0.47%)
AMC   40.80 (-5.18%)
QQQ   375.47 (+0.76%)
AAPL   148.76 (+1.51%)
MSFT   308.23 (+0.31%)
FB   339.99 (+1.39%)
GOOGL   2,864.74 (+0.32%)
TSLA   864.27 (-0.67%)
AMZN   3,444.15 (-0.08%)
NVDA   222.90 (+0.31%)
BABA   177.00 (+6.10%)
NIO   40.03 (+1.06%)
CGC   14.34 (+8.64%)
GE   104.73 (+0.59%)
AMD   116.33 (-0.09%)
MU   67.57 (+0.46%)
T   25.59 (+1.03%)
F   15.42 (-0.90%)
ACB   7.45 (+7.66%)
DIS   171.18 (+0.02%)
PFE   42.09 (+1.86%)
BA   215.97 (-0.47%)
AMC   40.80 (-5.18%)
QQQ   375.47 (+0.76%)
AAPL   148.76 (+1.51%)
MSFT   308.23 (+0.31%)
FB   339.99 (+1.39%)
GOOGL   2,864.74 (+0.32%)
TSLA   864.27 (-0.67%)
AMZN   3,444.15 (-0.08%)
NVDA   222.90 (+0.31%)
BABA   177.00 (+6.10%)
NIO   40.03 (+1.06%)
CGC   14.34 (+8.64%)
GE   104.73 (+0.59%)
AMD   116.33 (-0.09%)
MU   67.57 (+0.46%)
T   25.59 (+1.03%)
F   15.42 (-0.90%)
ACB   7.45 (+7.66%)
DIS   171.18 (+0.02%)
PFE   42.09 (+1.86%)
BA   215.97 (-0.47%)
AMC   40.80 (-5.18%)
NASDAQ:SRPT

Sarepta Therapeutics News Headlines

$80.44
-0.78 (-0.96 %)
(As of 10/19/2021 04:00 PM ET)
Add
Compare
Today's Range
$80.05
$82.59
50-Day Range
$73.32
$99.42
52-Week Range
$65.30
$181.83
Volume974,240 shs
Average Volume1.37 million shs
Market Capitalization$6.42 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.38

Media Mentions By Week

Sarepta Therapeutics Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

SRPT
News Sentiment

0.42

0.36

Average
Medical
News Sentiment

Media Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

SRPT Articles
This Week

19

4

SRPT Articles
Average Week

Get Sarepta Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for SRPT and its competitors with MarketBeat's FREE daily newsletter.

Sarepta Therapeutics (NASDAQ SRPT) News Headlines Today

SourceHeadline
marketbeat.com logoSarepta Therapeutics (NASDAQ:SRPT) Receives "Hold" Rating from Berenberg Bank
marketbeat.com - October 15 at 12:12 PM
nasdaq.com logoWhat's Next For Sarepta Stock After A 12% Fall?
nasdaq.com - October 19 at 7:55 AM
barrons.com logoPremarket Movers: dLocal, TaskUs, Sarepta Therapeutics
barrons.com - October 19 at 7:55 AM
forbes.com logoWhat’s Next For Sarepta Stock After A 12% Fall?
forbes.com - October 18 at 4:05 PM
markets.businessinsider.com logoExpert Ratings For Sarepta Therapeutics
markets.businessinsider.com - October 15 at 3:04 PM
MarketBeat logoSarepta Therapeutics (NASDAQ:SRPT) Given Hold Rating at Berenberg Bank
americanbankingnews.com - October 15 at 1:03 PM
fool.com logoWhy Sarepta Therapeutics Fell 14.7% This Week
fool.com - October 14 at 4:26 PM
MarketBeat logoSarepta Therapeutics (NASDAQ:SRPT) Sees Large Volume Increase
americanbankingnews.com - October 14 at 12:09 PM
MarketBeat logoSarepta Therapeutics, Inc. (NASDAQ:SRPT) Given Average Recommendation of "Buy" by Analysts
americanbankingnews.com - October 14 at 5:24 AM
finance.yahoo.com logoWhy Sarepta Therapeutics Tumbled Today
finance.yahoo.com - October 13 at 7:25 PM
MarketBeat logoSarepta Therapeutics (NASDAQ:SRPT) Shares Gap Down to $95.07
americanbankingnews.com - October 13 at 11:18 AM
benzinga.com logoSarepta Therapeutics' SRP-9001 Shows Sustained Functional Improvements in Multiple Studies of Patients with Duchenne
benzinga.com - October 13 at 4:24 AM
finance.yahoo.com logoSarepta Stock Sinks After Announcing a Stock Sale. It’s the Latest ‘Bad’ News.
finance.yahoo.com - October 12 at 10:26 PM
finance.yahoo.com logoSarepta Therapeutics Announces Proposed $500,000,000 Public Offering of Common Stock
finance.yahoo.com - October 12 at 5:25 PM
finance.yahoo.com logoSarepta Therapeutics Announces Preliminary Financial Results for the Third Quar-ter Ended September 30, 2021
finance.yahoo.com - October 12 at 5:25 PM
finance.yahoo.com logoShould I Buy Sarepta Therapeutics Inc (SRPT)?
finance.yahoo.com - October 12 at 12:24 PM
MarketBeat logoBTIG Research Boosts Sarepta Therapeutics (NASDAQ:SRPT) Price Target to $125.00
americanbankingnews.com - October 12 at 8:30 AM
MarketBeat logoBTIG Research Raises Sarepta Therapeutics (NASDAQ:SRPT) Price Target to $125.00
americanbankingnews.com - October 12 at 8:30 AM
MarketBeat logoSarepta Therapeutics (NASDAQ:SRPT) Receives Buy Rating from SVB Leerink
americanbankingnews.com - October 12 at 7:44 AM
MarketBeat logoSarepta Therapeutics (NASDAQ:SRPT) Given New $100.00 Price Target at Credit Suisse Group
americanbankingnews.com - October 12 at 7:44 AM
MarketBeat logoNeedham & Company LLC Reiterates "Buy" Rating for Sarepta Therapeutics (NASDAQ:SRPT)
americanbankingnews.com - October 12 at 7:44 AM
finance.yahoo.com logoSarepta Therapeutics’ SRP-9001 Shows Sustained Functional Improvements in Multiple Studies of Patients with Duchenne
finance.yahoo.com - October 11 at 12:58 PM
MarketBeat logoSarepta Therapeutics (NASDAQ:SRPT) Shares Down 5.5%
americanbankingnews.com - October 11 at 12:20 PM
nasdaq.com logoNotable ETF Outflow Detected - XBI, CYTK, CCXI, SRPT
nasdaq.com - October 7 at 12:23 PM
finance.yahoo.com logo'Means to an end' – This startup co-founder is happier post-acquisition
finance.yahoo.com - October 7 at 12:23 PM
MarketBeat logoSarepta Therapeutics (NASDAQ:SRPT) Now Covered by Analysts at Robert W. Baird
americanbankingnews.com - October 7 at 7:20 AM
MarketBeat logoSarepta Therapeutics (NASDAQ:SRPT) Trading 3% Higher
americanbankingnews.com - October 6 at 1:04 PM
finance.yahoo.com logo'Patients are waiting' – Sarepta opens Columbus R&D center (slideshow)
finance.yahoo.com - October 6 at 12:15 PM
finance.yahoo.com logoSarepta (SRPT) Begins Pivotal Study on DMD Gene Therapy
finance.yahoo.com - October 5 at 1:04 PM
finance.yahoo.com logoSarepta Therapeutics Opens Genetic Therapies Center of Excellence in Columbus, Ohio
finance.yahoo.com - October 4 at 5:00 PM
finance.yahoo.com logoSarepta Therapeutics Announces Initiation of EMBARK, a Global Pivotal Study of SRP-9001, a Gene Therapy for the Treatment of Duchenne Muscular Dystrophy
finance.yahoo.com - October 4 at 11:59 AM
finance.yahoo.com logoSRPT Oct 2021 88.500 call
finance.yahoo.com - October 2 at 3:21 AM
finance.yahoo.com logoSarepta Therapeutics to Initiate Part B of MOMENTUM Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping Following Positive Interactions with FDA
finance.yahoo.com - September 27 at 12:59 PM
finance.yahoo.com logoEven after rising 6.4% this past week, Sarepta Therapeutics (NASDAQ:SRPT) shareholders are still down 44% over the past three years
finance.yahoo.com - September 17 at 1:14 PM
finance.yahoo.com logoSarepta Therapeutics to Showcase Data from its Gene Therapy and RNA Platforms at World Muscle Society 2021 Virtual Congress
finance.yahoo.com - September 14 at 9:10 AM
nasdaq.com logoWhat Kind Of Shareholders Hold The Majority In Sarepta Therapeutics, Inc.'s (NASDAQ:SRPT) Shares?
nasdaq.com - September 10 at 5:03 PM
nasdaq.com logoOctober 29th Options Now Available For Sarepta Therapeutics (SRPT)
nasdaq.com - September 9 at 5:37 PM
nasdaq.com logoHow Does Sarepta's Stock Performance In The Current Crisis Compare With That In 2008?
nasdaq.com - September 8 at 4:31 AM
forbes.com logoHow Does Sarepta’s Stock Performance In The Current Crisis Compare With That In 2008?
forbes.com - September 7 at 9:55 AM
ca.finance.yahoo.com logoSRPT Sep 2021 84.000 call
ca.finance.yahoo.com - September 4 at 9:32 PM
finance.yahoo.com logoSarepta Therapeutics (SRPT) Up 1.2% Since Last Earnings Report: Can It Continue?
finance.yahoo.com - September 3 at 5:52 PM
barrons.com logoSarepta Stock Is Down 57% This Year. How the Biotech Could Make a Comeback.
barrons.com - August 26 at 4:53 PM
msn.com logo'Fast Money Halftime Report' Picks For August 24
msn.com - August 24 at 9:57 PM
barrons.com logoSarepta Is Down 57% This Year. One Investor Says It’s Coming Back.
barrons.com - August 24 at 9:57 PM
finance.yahoo.com logoCathie Wood is Getting Rid of These 10 Stocks
finance.yahoo.com - August 24 at 11:56 AM
finance.yahoo.com logoSarepta (SRPT) Q2 Earnings Beat, 2021 Sales View Raised
finance.yahoo.com - August 5 at 2:58 PM
feeds.marketwatch.com logo: Sarepta Therapeutics upgraded to neutral from underweight at J.P. Morgan
feeds.marketwatch.com - August 5 at 8:25 AM
fool.com logoSarepta Therapeutics (SRPT) Q2 2021 Earnings Call Transcript
fool.com - August 5 at 5:17 AM
nasdaq.com logoSarepta Therapeutics Q2 adjusted earnings Miss Estimates
nasdaq.com - August 4 at 6:46 PM
finance.yahoo.com logoSarepta Therapeutics Announces Second Quarter 2021 Financial Results and Recent Corporate Developments
finance.yahoo.com - August 4 at 6:46 PM
finance.yahoo.com logoSarepta Therapeutics Executes Licensing Agreement for Gene Therapy Program from Nationwide Children’s Hospital to Treat Limb-Girdle Muscular Dystrophy Type 2A
finance.yahoo.com - August 4 at 8:41 AM
Get Sarepta Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for SRPT and its competitors with MarketBeat's FREE daily newsletter.

This page was last updated on 10/19/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.